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Effects of H. pylori Treatment on Gastric Cancer Incidences in Older Individuals
A. Cumulative risk of gastric cancer in the HP 
treated cohort (n = 73,237) vs general population 
in Hong Kong* 
B. Cumulative risk of gastric cancer in the HP 
treated cohort vs general population according to 
age of treatment
C. Risk of gastric cancer in the HP treated cohort vs 
general population ≥10 years post-treatment
*based on Hong Kong Cancer Registry data
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ABSTRACT  
 
Background & Aims: Although eradication of Helicobacter pylori infection reduces the risk 
of gastric cancer, few data are available on its effects in older subjects. We compared the age-
specific risk of gastric cancer in a large cohort of subjects who received H pylori eradication 
therapy vs a matched general population. 
Methods: We searched the Hospital Authority database of Hong Kong to identify individuals 
with H pylori infection who had received a course of clarithromycin-containing eradication 
therapy from January 2003 through December 2012. We compared the gastric cancer 
incidence in this cohort with the expected incidence for the local general population by 
retrieving the gastric cancer incidence of the age- and sex-matched population from 2003 
through 2014 (the latest available year) from the Hong Kong Cancer Registry. The primary 
outcome was the incidence of gastric cancer development in the cohort treated for H pylori 
infection vs the expected number of gastric cancer cases in the general population. Analyses 
were conducted by a priori age groups of less than 40 years, 40–59 years, and 60 years or 
older. 
Results: Among 73,237 subjects infected with H pylori who received eradication therapy, 
200 (0.27%) developed gastric cancer during a median follow-up time of 7.6 years. 
Compared with the matched general population, the gastric cancer risk was significantly 
lower in subjects 60 years or older who had received H pylori treatment (standardized 
incidence ratio [SIR], 0.82; 95% CI, 0.69–0.97; P=.02) but not in younger groups. When data 
were stratified based on time from H pylori treatment (less than 5 years, 5–9 years, and 10 or 
more years), the risk of gastric cancer was significantly lower than the general population 10 
or more years after eradication in the group 40–59 years old (SI, 0.32; 95% CI 0.08–0.88; 
P=.04) and the group 60 years or older (SIR, 0.42; 95% CI 0.42–0.84; p = 0.02) than the 
other age groups. 
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Conclusions: In an analysis of data from a public hospital database on Hong Kong, we 
associated treatment of H pylori infection with a lower risk of gastric cancer, particularly in 
older subjects, 10 or more years after treatment. 
 
Keywords: chemoprevention; antibiotics; stomach cancer; bacteria 
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INTRODUCTION 
 
Gastric cancer is the fifth most common cancer in the world with approximately one million 
new cases diagnosed each year; and the majority are from less developed regions including 
Asia.1 Although the incidences of gastric cancer are generally declining, it is estimated that 
the total number of cases, or the actual disease burden, will maintain at a constant level for 
next few decades due to the ageing population.2  
 
Helicobacter pylori, which infects more than 50% of individuals in less developed regions,3 
has been identified as the major etiological factor for gastric cancer. H pylori associated 
gastric carcinogenesis involves a long process which progresses through multiple histological 
stages including chronic gastritis, atrophic gastritis, metaplastic mucosa, intramucosal 
neoplasia and finally invasive cancer. 4, 5 As the incidence of pre-neoplastic gastric lesions 
parallels with the increase in age,6, 7 the age at gastric cancer diagnosis is usually quite high 
In Hong Kong, the median age of gastric cancer diagnosis in men and women is 71 and 68 
years, respectively, with the corresponding age-standardized rate of 9.5 and 6.1 per 100,000 
population.8  
 
Recent meta-analyses have shown that eradication of H pylori reduces the incidence of 
gastric cancer by approximately 33-47%.9, 10 However, a randomized controlled trial from 
China suggested that patients with pre-existing pre-neoplastic lesions may not benefit from H 
pylori eradication in terms of gastric cancer prevention,11 implying a point of no return in the 
H pylori-associated gastric carcinogenesis cascade. In the Maastricht V Consensus Report, it 
is also recommended that the risk of developing gastric cancer can be reduced more 
effectively by employing eradication treatment before the development of atrophy and 
intestinal metaplasia 12. Although it is intuitive to give H pylori eradication therapy before the 
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development of pre-neoplastic gastric lesions for gastric cancer prevention, majority of older 
infected population already have some atrophic changes and the actual benefits of treating H 
pylori in these subjects remains uncertain. Because the increase in cancer risk increases 
exponentially with age, if eradication aborted the exponential increase, H pylori eradication 
should benefit the older age population and reduce their risk of developing gastric cancer.  
 
Based on a large cohort of H pylori infected subjects who had received clarithromycin-
containing eradication therapy in Hong Kong, we determined the age-stratified risk of gastric 
cancer development and compared with the expected gastric cancer risk in the matched local 
general population.   
 
 
METHODS 
Study Design and Data Source 
We identified subjects who had received a course of clarithromycin-containing triple therapy 
for H pylori infection between January 2003 and December 2012 in all public hospitals 
managed by the Hospital Authority in Hong Kong.13 The Hospital Authority is the sole public 
health service provider serving a local population of 7.3 million under a heavily subsidized 
public health care system.14 It manages 87% of all hospital beds in Hong Kong and has more 
than 7.5 million outpatient specialist consultations per year. These subjects were identified 
from the Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority 
which is a territory-wide health care database. The CDARS contained all essential clinical 
information including patients’ demographics, hospitalization, visits to outpatient clinics and 
emergency departments, diagnoses, laboratory results, procedures, prescriptions, dispensing 
of medications and death. Individual patient’s information is anonymized and each patient is 
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given a unique patient’s identifier in the CDARS. The International Classification of Diseases, 
Ninth Revision (ICD-9), was used for disease coding and our previous studies had verified 
the accuracy of the coding in CDARS with high positive and negative predictive values.15 
The study protocol was approved by the Institutional Review Board of the University of 
Hong Kong and the Hong Kong West Cluster of Hospital Authority, Hong Kong (reference 
no: UW 16-545).    
 
Subjects 
We identified all adults, aged 18 or above, who had been prescribed their first course of 
clarithromycin-containing triple therapy for H pylori infection. Treatment with 
clarithromycin triple therapy was identified by the co-prescription of one of the proton pump 
inhibitors (PPIs) with clarithromycin and either amoxicillin or metronidazole, with doses as 
described previously.17 The start date of the prescriptions should be the same, with an 
overlapping duration of 7 to 14 days. Since clarithromycin-containing triple therapy is the 
most commonly prescribed first-line therapy for H pylori in Hong Kong with a high success 
rate16, it is still the current first line treatment for H pylori. Treatment for H pylori with non-
clarithromycin-containing therapy as first-line treatment, mainly bismuth-based therapy, were 
only noted in 2,285 patients during the study period and hence were not included in this 
analysis. We excluded subjects who had prior history of gastrectomy, with gastric cancer 
prior to or within 12-month after receiving H pylori eradication therapy, or diagnosis of 
gastric ulcer after H pylori therapy as these may represent missed cancers. (Supplementary 
Figure 1).  
 
H pylori Treatment Outcomes 
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We performed subgroup analysis by dividing the H pylori treated subjects into two groups 
according to the treatment outcomes. As post-treatment H pylori status was not available in 
the CDRAS, we identified subjects who failed the first line clarithromycin-containing 
treatment and needed retreatment for H pylori. These subjects were identified by the 
subsequent prescription of another course of eradication therapies including a second line 
(bismuth-containing quadruple therapy or PPI-levofloxacin-amoxycillin) or a third line 
therapy (rifabutin-containing therapy) or a repeated prescription of clarithromycin-containing 
triple therapy with an overlapping duration of 7 to 14 days. This group of subjects who 
needed repeat treatment for H pylori was labelled the “Retreatment” group whereas the 
patients with a single course of clarithromycin-containing triple therapy were designated as 
the “Treatment Success” group in subsequent analysis.  
 
General population as the comparison group 
H pylori testing is not routinely performed in the local public health care system except in 
symptomatic patients such as dyspepsia or performed during upper endoscopic examinations 
for other reasons such as anemia work up. The currently available pre-treatment testing for H 
pylori included urea breath test and biopsy-based tests such as rapid urease test, histology and 
bacterial culture.  Serological tests and H pylori stool antigen tests are not available in local 
hospitals. Our current practices would treat all patients with confirmed H pylori infection. 
Hence, it would not be possible to identify a group of H pylori infected patients who had not 
received treatment for comparison. Instead, we compared the gastric cancer incidence in this 
H pylori treated cohort with the expected gastric cancer incidence in the local general 
population by retrieving the gastric cancer incidence of the age- and sex-matched population 
from year 2003 to 2014 (the latest available year) in the Hong Kong Cancer Registry8. This 
cancer registry is a population-based registry covering the entire local population and is one 
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of the accredited members of the International Association of Cancer Registries. The data 
available in the registry enabled the calculation of the expected number of gastric cancer 
cases in the study cohort after adjusting for the age and sex effect.  
 
Outcome  
The primary outcome was the incidence of gastric cancer development in the cohort treated 
for H pylori infection vs the expected number of gastric cancer cases in the general 
population. The date of diagnosis of gastric cancer (ICD-9 coding 151) for the study cohort 
was defined as the first date of hospitalization for gastric cancer workup or treatment. Other 
gastric malignancy including gastric lymphoma were not included.  
 
Statistical analyses 
Person-years at risk of gastric cancer were derived for each patient from the first date of 
clarithromycin-containing triple therapy until the date of gastric cancer diagnosis in the 
respective years or the date of censoring in this cohort. Patients were censored at death, 
diagnosis of gastric cancer or the end of 2015. All analyses were conducted by a priori age 
groups of <40 years, 40-59.9 years and ≥60 years.  
 
We estimated the standardized incidence ratio (SIR) and the expected cumulative incidence 
curve based on the methods outlined in Finkelstein et al.18 The mean incidence rates by five-
year age group in the years of 2003-2014 were used in this estimation. The observed number 
of gastric cancer cases was assumed to follow a Poisson distribution. The SIR was estimated 
in terms of the ratio of observed to expected gastric cancer cases with the exact 95% 
confidence interval (CI). One-sample log-rank test for incidence rates18 was used to contrast 
any statistical difference between the observed and the expected values. The observed 
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cumulative incidence curves for each age group were derived as the complement of the 
Kaplan-Meier survival curves. Stratified analyses were performed according to the treatment 
outcome (“Treatment Success” and “Retreatment”) and subject’s sex. A p value of 0.05 or 
less was used to indicate statistical significance. All analyses were performed by using R 
3.4.1. 
 
 
 
RESULTS 
Gastric cancer risk in the H pylori treated cohorts 
A total of 73,237 patients had received a course of clarithromycin-containing triple therapy 
for H pylori during the study period. The baseline characteristics of these patients are shown 
in Table 1. Among them, 9,840 (13.4%) patients needed re-treatment for H pylori, including 
130 patients who needed third-line therapy. The median duration from the time of 
prescription of clarithromycin-containing triple therapy to the second-line and third-line 
therapy was 1.5 years (IQR: 0.2 – 4.8) and 2.3 years (IQR: 1.1 – 4.9). The remaining 63,397 
patients who had no re-treatment for H pylori were included in the “Treatment Success” 
group (Supplementary Figure 1).  
 
Overall, 200 (0.27%) patients developed gastric cancer with a median follow-up of 7.6 (IQR 
5.1 to 10.3 years) and the overall incidence rate was 3.6 per 10,000 person-years). The 
number of gastric cancer cases in the “Treatment Success” and “Re-treatment” group was 
153 (0.24%; 3.2 per 10,000 person-years) and 47 (0.48%; 6.2 per 10,000 person-years), 
respectively.  The relative risk (RR) of gastric cancer in the Retreatment group as compared 
to the Treatment Success group was 2.0 (95% confidence interval (CI) 1.4 to 2.7; p <0.001).  
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The risks of gastric cancer after stratification by age of H pylori treatment, sex and treatment 
outcomes were shown in Table 2. The risk of gastric cancer was significantly higher in male 
subjects who received H pylori treatment at older age (≥60 years) than the corresponding 
female subjects (RR 1.8; 95% CI 1.3 to 2.6; p = 0.001). The risk of gastric cancer was also 
higher among middle-aged (40-59 years) subjects who required re-treatment for H pylori (RR 
2.5; 95% CI 1.4 to 4.4; p = 0.003).  
 
Comparison to the matched general population 
Figure 1A showed the cumulative incidence of gastric cancer in the whole H pylori treated 
cohort when compared to the expected gastric cancer incidence in the age- and sex-matched 
local population (p = 0.28), and Figure 1B showed the results after stratification by treatment 
outcomes. The “Treatment Success” group tended to have lower incidence of gastric cancer 
(p = 0.06) whereas the “Re-treatment” group tended to have a higher incidence than expected 
in the general population (p = 0.13).  
 
Table 3 compared the gastric cancer incidences in our cohort, after stratification by age of H 
pylori treatment, with the expected incidences from the matched general population. The 
incidence of gastric cancer was significantly lower than the general population in the older 
(≥60 years) age group (SIR, 0.82; 95% CI, 0.69 to 0.97; p=0.02) but not in the other two 
younger age groups (Figure 2). Similar results were observed in the Treatment Success group 
but not in the Re-treatment group (Table 3; Supplementary Figure 2). Notably, the SIR of 
gastric cancer among those receiving treatment between 40 and 59 years of the Re-treatment 
group was significantly higher than the corresponding general population (SIR, 2.43; 95% CI, 
1.44 to 3.86). As the difference in gastric cancer risk was observed in older subjects, stratified 
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analysis was conducted according to patient’s sex in this group (Male, SIR: 0.81 [0.65 -1.00], 
p=0.05; Female, SIR: 0.84 [0.62 – 1.12], p=0.25).  
 
Follow-up durations after H pylori treatment and risk of gastric cancer 
We also determined the risk of gastric cancer during different time points after H pylori 
treatment (<5, 5-9 and ≥10 years). The incidences of gastric cancer in the H pylori-treated 
cohort were comparable to the age-matched general population in the first 10 years’ after 
eradication (Figures 3A and 3B). However, after ≥10 years of H pylori treatment, the risk of 
gastric cancer among the older (≥60years) and middle (40-59 years) age groups became 
significantly lower than the matched general population (≥60 years: SIR 0.42, 95% CI 0.18 to 
0.84; and 40-59 years: SIR 0.32, 95% CI 0.08 to 0.88; Figure 3C). Similar results were 
observed among the Treatment Success group (Table 4; Supplementary Figure 3).  
 
 
 
 
DISCUSSION 
 
The results from this territory-wide study from Hong Kong provides strong support that H 
pylori treatment, even when given to those aged 60 or above who are the highest risk group, 
could still lower the risk of gastric cancer development. When compared to matched general 
population, which comprises of both H pylori-infected and non-infected individuals, the risk 
of gastric cancer was reduced by 18% in the older (≥60) age group who had received H pylori 
treatment. When further stratified by the time from H pylori treatment, the risk reduction was 
more significant ≥10 years after receiving eradication therapy. Since both H pylori infection 
and gastric cancer are more prevalent among the older populations, these findings carry 
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major clinical and public health impact that even older subjects would still benefit from 
eradication therapy.   
 
H pylori infection, which is usually acquired early in life, leads to chronic gastric 
inflammation in all, and gastric cancer in a small proportion of subjects. If left untreated, 
most subjects would remain infected unless they reach a stage of severe atrophy that is 
unfavourable for H pylori to thrive. Treatment of H pylori have been shown, in recent meta-
analyses,9, 10 to reduce the risk of gastric cancer by at least 33%.  While treatment before 
atrophy develops should prevent most of the subsequent cancers, the role, if any, of H pylori 
eradication therapy after development of pre-neoplastic changes is unclear. For example, the 
study by Wong et al. suggested that individuals with pre-existing pre-neoplastic gastric lesion 
still progressed to gastric cancer despite eradication of H pylori.11 In contrast, H pylori 
eradication even after endoscopic resection of early gastric cancer, which should be 
associated with concurrent pre-neoplastic lesions in the remaining stomach, has been shown 
to reduce development of metachronous cancers.19 Our findings therefore provide further 
support that eradication therapy given in later part of life could still significantly reduce the 
risk of gastric cancer development. The findings of significant difference in gastric cancer 
incidence in the older age group are not unexpected as the gastric cancer incidence is 
generally very low among the younger age group and increases exponentially with age. Early 
treatment at the time of exponential increase would be expected to have the greatest 
numerical effect on gastric cancer in that the risk would likely be stabilized at the time of 
eradication whereas the untreated would continue to increase in risk20. Although subsequent 
gastric cancer risk is not totally prevented by H pylori eradication therapy, the gastric cancer 
incidence is still significantly lower among older subjects. These results are consistent with 
results of the long-term follow-up of a randomized trial from China which showed that H 
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pylori treatment could still benefit subjects older than 55 years in terms of gastric cancer 
prevention with an odds ratio of 0.36 against those receiving placebo.21 Importantly, our 
study showed that the risk of gastric cancer in the older eradicated group was actually lower 
than that of the matched general population which included both H pylori infected and non-
infected subjects. While it is estimated that the local prevalence of H pylori infection to be 
about 56%,3 the expected population gastric cancer risk in the matched general population 
should be substantially lower than the risk of gastric cancer of our H pylori infected cohort.  
 
Our results showed that the risk of gastric cancer decreased with longer time lapsed from H 
pylori eradication therapy, consistent with eradication aborting or markedly decreasing the 
exponential increase in cancer experienced by the untreated subjects. Ten years after 
eradication, the risk of gastric cancer was 58% lower in the ≥60 years group and 68% lower 
in the 40-59 year groups when compared to the age- and sex-matched general population. 
The risks were even lower in these two age groups with treatment success (Table 3). 
Although there was no significant difference in the gastric cancer risk of the younger age 
group (<40 years), the risk of gastric cancer was actually very low in this age group which 
reflects the relative slow annual increase in gastric cancer in young subjects. It is therefore 
particularly important to determine the long-term risk of gastric cancer in this younger age 
group to confirm whether early H pylori eradication could possibly eliminate gastric cancer 
in future studies.  
 
We showed that those who received re-treatment for H pylori after failure of clarithromycin-
containing triple therapy had a two-fold increase in risk of gastric cancer development as 
compared to those with treatment success. This group largely consisted of individuals who 
have delayed rather than actual failure of eradication.  These results are consistent with a 
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study from Taiwan showing a marked difference in gastric cancer risks on early versus 
delayed H pylori eradication.22 In particular, the risk of gastric cancer among the middle (40-
59) age group who required retreatment in this study was significantly higher than general 
population (SIR = 2.43). Due to the long lag time of H pylori eradication to prevent gastric 
cancer development as shown in Figure 3, H pylori should be given earlier to maximize the 
potential benefits of H pylori eradication.  
 
This study has several strengths. First, this is a territory-wide study that included more than 
73,000 unselected H pylori infected subjects who had received a course of clarithromycin-
containing triple therapy for H pylori in Hong Kong with follow-up of up to 13 years. It is in 
marked contrast to previous randomized trials that included a relatively small number of 
high-risk patients only. Second, with the use of a very comprehensive electronic health 
database of the Hong Kong Hospital Authority that has been used to publish high quality 
studies previously,8, 15, 23, we were able to determine the risk of gastric cancer in subjects 
according to age of H pylori treatment. We further utilized the gastric cancer incidence data 
from the Hong Kong Cancer Registry, a population registry, to estimate the expected gastric 
cancer incidences in the age- and sex-matched local population, which comprises of both H 
pylori-positive and negative subjects. Although the Cancer Registry includes all cancer 
patients in Hong Kong and the Hospital Authority is responsible for about 90% of the local 
health care services only, most cancer patients would be managed under the Hospital 
Authority due to resource and cost issues.  
 
At the same time, this study has limitations. First, we did not have a similar cohort of 
untreated H pylori-infected subjects as the comparison group. As the local practices are to 
treat all H pylori-infected subjects, these untreated subjects would not be available as control. 
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Instead, we compared the risk of gastric cancer in our cohort with the general population in 
Hong Kong based on data from the Hong Kong Cancer Registry. Even with the inclusion of 
both H pylori infected and non-infected subjects in the general population, we could still 
demonstrate a significantly lower risk of gastric cancer among the older subjects who had 
received treatment for H pylori. Second, the baseline histology of these subjects was not 
available in the electronic database and hence we could not further stratify the gastric cancer 
risk according to baseline gastric pathology. However, it is anticipated that the percentage of 
patients with pre-neoplastic gastric lesions would increase with ages 6,7 and a large proportion 
of our H pylori infected subjects would harbour pre-neoplastic lesions in the stomach. Third, 
while H pylori infection is more associated with non-cardia gastric cancer, the analysis 
should include subgroup analysis according to tumor location. However, information on 
tumor location is not available in the Hong Kong Cancer Registry, hence further analysis 
regarding non-cardia cancer was not possible. Fourth, although it is a routine local practice to 
check for H pylori status after treatment, this piece of information is not available in the 
electronic database. Hence, we could only broadly classify the treatment outcome based on 
need of re-treatment. The overall re-treatment rate in this cohort was 13.4%, which is 
comparable to the reported treatment success rate of clarithromycin-containing triple therapy 
during the study period in Hong Kong.16 Moreover, the primary analysis included all patients 
who had received H pylori treatment rather than restricted to those with successful 
eradication only. Lastly, we only included patients who had received clarithromycin-
containing triple therapy in this analysis as this regimen is still, up to this moment, the most 
commonly prescribed first-line treatment for H pylori in Hong Kong. During this study 
period, only 2,285 (or 3% of all first-line therapy for H pylori) of subjects were given non-
clarithromycin containing therapy as first line therapy for H pylori.   
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In conclusion, our findings from this territory-wide cohort study support the notion that 
although prevention of most gastric cancers may require treatment before the onset of 
atrophic changes, H pylori eradication could still reduce gastric cancer development in the 
older populations. There was a 18% reduction in gastric cancer incidences among older (≥60 
years of age) subjects who had received H pylori treatment, when compared to matched 
general population who may not even have H pylori infection and hence a low risk of gastric 
cancer. Our findings would be in strong support for H pylori eradication in all age groups to 
prevent gastric cancer development.  
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FIGURE LEGEND 
 
 
Figure 1: Cumulative gastric cancer incidences in the H pylori treated subjects as 
compared with the expected gastric cancer incidence in the general population for the 
(A) whole cohort (n = 73,237) and (B) according to treatment outcomes (treatment 
success vs re-treatment).  
 
“Expected” refers to the expected number of cases for individuals in the general population 
with similar age and sex of the entire cohort based on data from the Hong Kong Cancer 
Registry.  
 
 
Figure 2: Cumulative incidences of gastric cancer in all H pylori treated subjects (n = 
73,237), after stratification by age of treatment, as compared with the expected 
cumulative incidence in the matched general population.  
 
The curves were censored at 13 years. The expected number of gastric cancer cases was 
calculated using data from the Hong Kong Cancer Registry on individuals in the general 
population with similar age and sex.    
 
 
 
 
Figure 3: Observed (red line) and expected (black line) incidence rates of gastric cancer 
in all H pylori treated subjects (n = 73,237) and matched general population, according 
to age and follow-up durations.  
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Table 1: The baseline characteristics of all H pylori treated subjects  
 Whole cohort 
(n=73,237) 
Age at triple therapy  55.2 (46.3 – 66.5)* 
Male sex  34345 (46.9%) 
Duration of follow-up in years  7.6 (5.1 – 10.3)* 
History of gastric ulcer  1620 (2.2%) 
History of duodenal ulcer  2277 (3.1%) 
Upper endoscopy at diagnosis of H pylori infection  60,948 (83.2%) 
Upper endoscopy during follow-up   25,738 (35.1%) 
Need retreatment for H pylori  9840 (13.4%) 
Diabetes mellitus  9243 (12.6%) 
Hypertension 16293 (22.2%) 
Dyslipidemia 6243 (8.5%) 
Ischemic heart disease 7312 (10.0%) 
Atrial fibrillation 3200 (4.4%) 
Congestive heart failure 3542 (4.8%) 
Cirrhosis 1305 (1.8%) 
* interquartile range (IQR) 
Numbers in brackets are percentage unless specified 
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Table 2. Comparison of the risks of gastric cancer in the H pylori eradication cohort 
according to subject’s sex and treatment outcomes. 
 
 
 Age 
group 
Number 
of subjects 
Person-
years at risk 
Observed 
number of 
cases 
Relative risk 
(95% CI) 
p value* 
 
Sex 
 
Male <40 yr 4,376 37,003 2 1.2 (0.2-8.7) >0.99 
Female  5,377 44,710 2   
       
Male 40-59 yr 15,855 126,740 34 1.3 (0.8-2.0) 0.33 
Female  20,206 160,577 34   
       
Male ≥60 yr 14,114 94,813 84 1.8 (1.3-2.6) 0.001 
Female  13,309 95,458 44   
       
 
Treatment Outcome 
 
Re-treatment <40 yr 1,111 9,701 1 2.6 (0.3-24.9) 0.38 
Treatment Success 8,642 72,012 3   
       
Re-treatment 40-59 yr 3,936 32,370 16 2.5 (1.4-4.4) 0.003 
Treatment Success 32,125 254,947 52   
       
Re-treatment ≥60 yr 4,793 33,970 30 1.4 (0.9-2.2) 0.08 
Treatment Success 22,630 156,301 98   
       
 
* Fisher’s exact test was used to compare the observed incidence in the two treatment groups (success/re-treatment), 
for each age group.  
 
yr, year 
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Table 3. Observed number of gastric cancer cases in the H pylori treated subjects and the 
expected number of gastric cancer cases in the general population as stratified by age of H 
pylori eradication and treatment outcomes.* 
 
 
HP treatment cohort 
 
General population 
Treatment 
outcome 
Age 
group 
Number 
of 
subjects 
Person-
years at 
risk 
Observed 
number 
of cases 
Expected 
number 
of cases 
SIR (95% CI) p value 
        
All treated 
patients 
(n = 73237) 
<40 yr 9,753 81,713 4 3.0 1.34 (0.43-3.24) 0.55 
40-59 yr 36,061 287,317 68 56.8 1.20 (0.94-1.51) 0.14 
≥60 yr  27,423 190,271 128 156.1 0.82 (0.69-0.97) 0.02 
        
        
Treatment 
Success 
(n = 63397) 
<40 yr 8,642 72,012 3 2.6 1.15 (0.29-3.13) 0.81 
40-59 yr  32,125 254,947 52 50.2 1.04 (0.78-1.35) 0.80 
≥60 yr  
 
22,630 156,301 98 125.2 0.78 (0.64-0.95) 0.01 
        
Retreatment 
(n = 9840) 
<40 yr  1,111 9,701 1 0.4 2.70 (0.13-13.29) 0.30 
40-59 yr  3,936 32,370 16 6.6 2.43 (1.44-3.86) <0.001 
≥60 yr  
 
4,793 33,970 30 30.9 0.97 (0.67-1.37) 0.88 
 
*Data on gastric cancer incidence in the general population are from the Hong Kong Cancer Registry. The incidence 
tables gave annual incidence rates for each sex in 5-year age categories. For each 5-year category, the mean 
incidence rate between 2003 and 2014 (the latest available year) was used. The Standardized Incidence Ratio (SIR) 
is for the cohort as compared with the general population. 
 
HP, Helicobacter pylori; yr, year 
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Table 4. Gastric cancer incidence in the H pylori treated patients as compared with gastric 
cancer incidence in the general population, stratified by age of H pylori eradication and 
year of follow-up.* 
 
HP treatment cohort 
 
General population 
Age 
group 
Year of 
follow-up 
Number 
of 
subjects 
Person-
years at 
risk 
Observed 
number 
of cases 
Expected 
number 
of cases 
SIR (95% CI) p value 
  
      
All treated patients (n = 73,237) 
 
<40 yr <5  9,753 38,948 3 1.0 3.14 (0.80-8.55) 0.04 
 5-9  8,076 33,646 1 1.4 0.73 (0.04-3.60) 0.75 
 ≥10  3,517 9,124 0 0.6 0.00 (0.00-4.61) 0.42 
  
      
40-59 yr <5  36,061 143,157 32 21.7 1.48 (1.03-2.06) 0.03 
 5-9  28,757 116,811 33 25.9 1.28 (0.89-1.77) 0.16 
 ≥10  10,851 27,439 3 9.2 0.32 (0.08-0.88) 0.04 
  
      
≥60 yr <5  27,423 103,602 66 74.4 0.89 (0.69-1.12) 0.33 
 5-9  18,943 72,987 55 65.2 0.84 (0.64-1.09) 0.21 
 ≥10 5,747 14,198 7 16.6 0.42 (0.18-0.84) 0.02 
        
Treatment success group (n = 63,397) 
 
<40 yr <5 8,642 34,500 2 0.8 2.37 (0.40-7.84) 0.21 
 5-9 7,114 29,538 1 1.2 0.84 (0.04-4.12) 0.86 
 ≥10 3,076 7,979 0 0.6 0.00 (0.00-5.30) 0.45 
        
40-59 yr <5 32,125 127,592 25 19.3 1.30 (0.86-1.89) 0.19 
 5-9 25,488 103,252 26 22.8 1.14 (0.76-1.65) 0.50 
 ≥10 9,551 24,181 1 8.1 0.12 (0.01-0.61) 0.01 
        
≥60 yr < 5 22,630 85,519 51 59.8 0.85 (0.64-1.11) 0.25 
 5-9 15,510 59,648 42 52.1 0.81 (0.59-1.08) 0.16 
 ≥ 10 4,685 11,586 5 13.3 0.37 (0.14-0.83) 0.02 
        
 
* Data on gastric cancer incidence in the general population are from the Hong Kong Cancer Registry. The 
incidence tables gave annual incidence rates for each sex in 5-year age categories. For each 5-year category, the 
mean incidence rate between 2003 and 2014 (the latest available year) was used. The Standardized Incidence Ratio 
(SIR) is for the cohort as compared with the general population. 
 
HP, Helicobacter pylori 
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Patients received clarithromycin-
based triple therapy between Jan 
2003 and Dec 2012
(n = 74,612)
Age <18 
(n = 451)
GC* diagnosed 
before triple 
therapy (n = 5)
GC diagnosed within 
1 year of triple 
therapy (n= 550)
Patients with 
gastrectomy
(n = 161) Gastric ulcer at or 
after triple therapy
(n = 208)
Eligible patients
(n = 73,237)
Treatment success 
group 
( n= 63,397)
Re-treatment group
(n = 9,840)
3rd line treatment
( n= 130)
Supplementary Figure 1:
Patient’s recruitment flow diagram
*GC = gastric cancer
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(A) Treatment success (n=63,397) (B) Re-treatment (n=9,840)
p = 0.01
p = 0.81
p = 0.80
p < 0.001
p = 0.88
p = 0.30
Supplementary Figure 2: Cumulative incidences of gastric cancer in all H. pylori treated subjects, after 
stratification by age of treatment and treatment outcomes, as compared with the expected cumulative incidence in 
the matched general population. 
The curves were censored at 13 years. The expected number of gastric cancer cases was calculated using data from the Hong Kong Cancer Registry on individuals in 
the general population with similar age and sex.   
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Supplementary Figure3: Observed (red line) and expected (black line) incidence rates of gastric cancer in 
patients successfully treated with H. pylori (n = 63,397) and matched general population, according to age 
and follow-up durations.
(A) Years of follow up: <5 (B) Years of follow up: 5-9 (C) Years of follow up: ≥10 
**p = 0.01
*p = 0.02
**
*
